The national lupus patient advocacy community is excited to announce that people with lupus will have the chance to be part of a history-making project that includes a meeting called Lupus: Patient Voices on September 25 in the Washington, D.C. area. This very important effort is a tremendous opportunity for individuals with lupus to contribute to lupus drug development […] READ MORE
10 New Grants, 10 New Insights The path to safe and effective treatments and ultimately a cure lies in bold, pioneering research. The Lupus Research Alliance Novel Research Grants, the proven platform for innovation, make discovery and scientific progress possible. “Standing on a 16-year foundation of documented success, the Novel Research Grants bring new insight […] READ MORE
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial met the complete and partial remission (“CR”/ “PR”) endpoints, demonstrating statistically significantly greater CR […] READ MORE
